Loading...
•
Dec 31, 2023
Vaxart Q4 2023 Earnings Report
Vaxart reported full year financial results and provided a business update.
Key Takeaways
Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022. Revenue for the full year 2023 was $7.4 million, compared to $0.1 million for 2022. Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
Vaxart made significant progress in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator
Topline data from Phase 1 norovirus study in lactating mothers expected in mid-2024
Steven Lo appointed President, Chief Executive Officer and Board Member
BARDA awarded Vaxart a $9.27 million contract in January to prepare for a 10,000-subject, Phase 2b clinical study
Revenue by Segment
Forward Guidance
Vaxart anticipates cash runway into the fourth quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...